Prospective Study
Copyright ©The Author(s) 2018.
World J Gastroenterol. Mar 21, 2018; 24(11): 1269-1277
Published online Mar 21, 2018. doi: 10.3748/wjg.v24.i11.1269
Table 1 Demographic and clinical characteristics of the chronic hepatitis C patients prior to direct-acting antivirals treatment and after achieving sustained virological response 12 n (%)
Prior to DAA treatment (baseline)Post-SVR 12P1 value
Demographics
Male49 (48)49 (48)NS
Age (yr, mean ± SD)60.3 ± 10.760.3 ± 10.7NS
White37 (37)37 (37)NS
Hispanic26 (26)26 (26)NS
African American13 (13)13 (13)NS
Asian7 (7)7 (7)NS
Other2 (2)2 (2)NS
Declined16 (15)16 (15)NS
Clinical
Hypertension45 (43)45 (43)NS
Type 2 diabetes13 (12.3)13 (12.3)NS
Dyslipidemia8 (7.5)8 (7.5)NS
Anthropometric (mean ± SD)
Body mass index (kg/m2)27.6 ± 6.927.5 ± 6.9NS
Weight (Lbs.)174.9 ± 46.9172.7 ± 44.5NS
Laboratory panel (mean ± SD)
HCV vial load log10 IU/mL6.2 ± 0.90.0 ± 0.0< 0.0001
HCV genotype
Genotype 186 (85)
Genotype 215 (14)
Genotype 41 (1)
AST (U/L)51.8 ± 41.121.5 ± 8.0< 0.0001
ALT (U/L)63.1 ± 62.617.8 ± 12.3< 0.0001
Alkaline phosphatase (U/L)77.5 ± 34.071.0 ± 24.30.004
Albumin (g/dL)4.3 ± 0.44.4 ± 0.4NS
Bilirubin, total (mg/dL)0.6 ± 0.20.6 ± 0.3NS
Fasting glucose (mg/dL)99.1 ± 30.1102.1 ± 23.5NS
FibroScan (mean ± SD)
Fibrosis Score (kPa)7.4 ± 1.96.1 ± 3.60.013
IQR (%)12.6 ± 4.912.3 ± 5.5NS